Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
NCT00064753 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
Conditions Studied
Interventions
- DRUG High Dose Multivitamin
- DEVICE Low Dose Multivitamin
Study Locations (20)
California
- Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation — Los Angeles
- University of California at Los Angeles — Los Angeles
- University of California at San Francisco — San Francisco
Minnesota
- Hennepin County Medical Center — Minneapolis
- Faireview University Medical Center — Minneapolis
- Mayo Clinic — Rochester
Illinois
- Northwestern University — Chicago
- Southern Illinois University — Springfield
New York
- Albany Medical Center — Albany
- State University of New York Downstate Medical Center — Brooklyn
Alabama
- University of Alabama at Birmingham School of Medicine — Birmingham
Arizona
- Banner Good Samaritan Transplant — Phoenix
Indiana
- Indiana University — Indianapolis
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,110 participants |
| Start Date | 2002-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064753
The ClinicalTrials.gov registry entry for NCT00064753 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 4,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 375 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions — of which High Dose Multivitamin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00064753 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Minnesota, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00064753 about?
NCT00064753 is a clinical study titled "Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)". The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
What is the current status of trial NCT00064753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,110 participants. The study started on 2002-05. Estimated completion is 2011-10.
What conditions does trial NCT00064753 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Chronic Kidney Disease, Death. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00064753?
The interventions under investigation include: High Dose Multivitamin (DRUG), Low Dose Multivitamin (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00064753?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 375 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00064753 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.